MEK-Inhibitor-assoziierte Retinopathie unter Binimetinib-Therapie bei kutanem malignem Melanom

S. Groselli; D. Heinrich; C. P. Lohmann; M. Maier

doi:10.1007/s00347-020-01089-3

MEK-Inhibitor-assoziierte Retinopathie unter Binimetinib-Therapie bei kutanem malignem Melanom

Translated title of the contribution: MEK inhibitor-associated retinopathy under binimetinib treatment for cutaneous malignant melanoma

S. Groselli, D. Heinrich, C. P. Lohmann, M. Maier

Default

Technical University of Munich

Research output: Contribution to journal › Article › peer-review

Abstract

The treatment options for patients with metastatic melanoma (MM) have been dramatically expanded in recent years with the approval of new drugs. The MEK (mitogen-acitvated protein kinase kinase) and BRAF (serine/threonine-protein kinase B-Raf coding gene) inhibitor combination therapy is currently part of the standard of care for stage IIIC/IV of BRAF mutant melanoma. The MEK inhibitor-associated retinopathy (MEKAR) is observed in patients with MM who are treated (or have been treated) with such a combination therapy. This article reports the case of a 72-year-old male patient, who suffered from such a pathological condition under treatment with binimetinib in combination with nivolumab. This case study illustrates the importance of interdisciplinary collaboration in the treatment of MM patients.

Translated title of the contribution	MEK inhibitor-associated retinopathy under binimetinib treatment for cutaneous malignant melanoma
Original language	German
Pages (from-to)	169-174
Number of pages	6
Journal	Ophthalmologe
Volume	118
Issue number	2
DOIs	https://doi.org/10.1007/s00347-020-01089-3
State	Published - Feb 2021

Access to Document

10.1007/s00347-020-01089-3

Cite this

@article{06fa7d641dee490fa8aedb927a6b9743,

title = "MEK-Inhibitor-assoziierte Retinopathie unter Binimetinib-Therapie bei kutanem malignem Melanom",

abstract = "The treatment options for patients with metastatic melanoma (MM) have been dramatically expanded in recent years with the approval of new drugs. The MEK (mitogen-acitvated protein kinase kinase) and BRAF (serine/threonine-protein kinase B-Raf coding gene) inhibitor combination therapy is currently part of the standard of care for stage IIIC/IV of BRAF mutant melanoma. The MEK inhibitor-associated retinopathy (MEKAR) is observed in patients with MM who are treated (or have been treated) with such a combination therapy. This article reports the case of a 72-year-old male patient, who suffered from such a pathological condition under treatment with binimetinib in combination with nivolumab. This case study illustrates the importance of interdisciplinary collaboration in the treatment of MM patients.",

keywords = "BRAF inhibitor, Neurosensory retinal detachment, Optical coherence tomography, Retinopathy, Side effects",

author = "S. Groselli and D. Heinrich and Lohmann, {C. P.} and M. Maier",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2021",

month = feb,

doi = "10.1007/s00347-020-01089-3",

language = "Deutsch",

volume = "118",

pages = "169--174",

journal = "Ophthalmologe",

issn = "0941-293X",

publisher = "Springer Medizin",

number = "2",

}

TY - JOUR

T1 - MEK-Inhibitor-assoziierte Retinopathie unter Binimetinib-Therapie bei kutanem malignem Melanom

AU - Groselli, S.

AU - Heinrich, D.

AU - Lohmann, C. P.

AU - Maier, M.

PY - 2021/2

Y1 - 2021/2

N2 - The treatment options for patients with metastatic melanoma (MM) have been dramatically expanded in recent years with the approval of new drugs. The MEK (mitogen-acitvated protein kinase kinase) and BRAF (serine/threonine-protein kinase B-Raf coding gene) inhibitor combination therapy is currently part of the standard of care for stage IIIC/IV of BRAF mutant melanoma. The MEK inhibitor-associated retinopathy (MEKAR) is observed in patients with MM who are treated (or have been treated) with such a combination therapy. This article reports the case of a 72-year-old male patient, who suffered from such a pathological condition under treatment with binimetinib in combination with nivolumab. This case study illustrates the importance of interdisciplinary collaboration in the treatment of MM patients.

AB - The treatment options for patients with metastatic melanoma (MM) have been dramatically expanded in recent years with the approval of new drugs. The MEK (mitogen-acitvated protein kinase kinase) and BRAF (serine/threonine-protein kinase B-Raf coding gene) inhibitor combination therapy is currently part of the standard of care for stage IIIC/IV of BRAF mutant melanoma. The MEK inhibitor-associated retinopathy (MEKAR) is observed in patients with MM who are treated (or have been treated) with such a combination therapy. This article reports the case of a 72-year-old male patient, who suffered from such a pathological condition under treatment with binimetinib in combination with nivolumab. This case study illustrates the importance of interdisciplinary collaboration in the treatment of MM patients.

KW - BRAF inhibitor

KW - Neurosensory retinal detachment

KW - Optical coherence tomography

KW - Retinopathy

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=85084679249&partnerID=8YFLogxK

U2 - 10.1007/s00347-020-01089-3

DO - 10.1007/s00347-020-01089-3

M3 - Artikel

C2 - 32248296

AN - SCOPUS:85084679249

SN - 0941-293X

VL - 118

SP - 169

EP - 174

JO - Ophthalmologe

JF - Ophthalmologe

IS - 2

ER -

MEK-Inhibitor-assoziierte Retinopathie unter Binimetinib-Therapie bei kutanem malignem Melanom

Abstract

Access to Document

Other files and links

Fingerprint

Cite this